IL-6/GP130/JAK/STAT3 Pathway Activation in Pancreatic Ductal Adenocarcinoma and Its Association With Clinical Features: Protocol for a Retrospective Cross-Sectional Study
Authors:
- Claudia MellenthinClaudia Mellenthin
- Fabien SchallerFSFabien Schaller
- Lucie VignotLVLucie Vignot
- Sarah PeislSPSarah Peisl
- Rita VesceRVRita Vesce
- Irene EspositoIrene Esposito
- Carmen Gonelle-GispertCGCarmen Gonelle-Gispert
- Cornelia SchneiderCSCornelia Schneider
- Michel AdaminaMAMichel Adamina
- Leo Hans BühlerLBLeo Hans Bühler
Open Access
- 15 December 2025
- journal article
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 14, e76811
Abstract
Background: The proinflammatory cytokine interleukin 6 (IL-6) contributes to pancreatic tumorigenesis by activating the Janus kinase (JAK)–signal transducer and activator of transcription 3 (STAT3) signaling cascade. Targeting the IL-6/glycoprotein 130 (GP130)/JAK/STAT3 axis may therefore represent a promising therapeutic approach for pancreatic adenocarcinoma. Objective: This study investigates the activation of the IL-6/GP130/JAK/STAT3 pathway in archived biopsy samples from patients with pancreatic adenocarcinoma, quantifying its expression in both tumor and stromal compartments. In addition, potential associations between pathway activation and clinical outcomes are explored, including tumor stage, patient survival, and metabolic parameters such as diabetes, use of oral antidiabetic drugs, insulin therapy, and hemoglobin A 1c levels. Methods: We will conduct a retrospective cross-sectional analysis of patients with pancreatic adenocarcinoma treated at the Cantonal Hospital of Fribourg, Switzerland, between 2010 and 2025. Eligible cases are identified through tumor board records. Archived pathology specimens will be immunostained using a phospho-STAT3 antibody to assess GP130 receptor activation. The percentage of positively stained cells will be quantified separately for tumor tissue, stroma, and adjacent normal tissue using QPath software. Sample size calculations are based on the assumption that patients with higher IL-6 pathway activation have poorer prognoses. Detecting a 5% difference in activation requires 84 patients per group for 90% power or 104 per group for 95% power. Diabetes will be analyzed as a dichotomous variable, while IL-6/GP130/JAK/STAT3 activation will be treated as a continuous variable. Descriptive statistics will summarize pathway activation and clinical variables. Mean differences between groups will be compared, and survival outcomes will be evaluated using Cox proportional hazards models. Hazard ratios will be calculated for all metabolic parameters to assess potential associations between pathway activation and diabetes. All analyses will include 95% CIs, with missing data reported transparently. Results: This project is supported by a research grant from the Cantonal Hospital of Fribourg (HFR 2/2021 and 4/2022). It was approved by the Ethics Committee of Bern, Switzerland (project 2024‐01215). As of October 12, 2025, clinical records from 150 patients have been identified. Screening of additional patient records from 2024 to 2025 is ongoing. Conclusions: This study represents one of the first translational investigations of IL-6/GP130/JAK/STAT3 signaling in pancreatic adenocarcinoma. By correlating molecular pathway activation with clinical and metabolic features, it will provide new insights into disease heterogeneity and support the development of personalized, pathway-targeted therapeutic strategies.Keywords
This publication has 22 references indexed in Scilit:
- A STAT3/integrin axis accelerates pancreatic cancer initiation and progressionCell Reports, 2025
- Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trialThe Lancet Gastroenterology & Hepatology, 2022
- Gp130 is expressed in pancreatic cancer and can be targeted by the small inhibitor molecule SC144Journal of Cancer Research and Clinical Oncology, 2022
- The Interplay Among Pancreatic Cancer, Cachexia, Body Composition, and DiabetesHematology/Oncology Clinics of North America, 2022
- Interleukin 6/gp130 axis promotes neural invasion in pancreatic cancerCancer Medicine, 2022
- Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trialThe Lancet, 2017
- Stat3/Socs3 Activation by IL-6 Transsignaling Promotes Progression of Pancreatic Intraepithelial Neoplasia and Development of Pancreatic CancerCancer Cell, 2011
- Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid vs Gemcitabine Following Pancreatic Cancer ResectionJAMA, 2010
- Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trialThe Lancet, 2001
- Portal but not peripheral serum levels of interleukin 6 could interfere with glucose metabolism in patients with pancreatic cancerClinica Chimica Acta, 1998